clinical trial · NCT06679985
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Hepatocellular CarcinomaCasdozokitugToripalimabBevacizumab
brief summary
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
started
Dec 20, 2024
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Apr 13, 2026
official title
A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol